Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 20, 2025Journal of Pioneering Medical Science

Elucidating Astragaloside IV's Anti-Glioma Action via Network Pharmacology, Molecular Docking, and Experimental Evidence for PI3K/AKT Pathway Inhibition

View Full Paper
Ask AI
Bookmark
Share

Authors

TWTing WangJHJing HanRSRong Su

Discussion

Loading...

Member takes

Overview

Research reveals astragaloside IV's potential to inhibit glioma via pi3k/akt pathway modulation, suggesting new therapeutic avenues.

Key Points

  • Astragaloside IV significantly reduces glioma cell proliferation and invasion, promoting apoptosis.
  • Cell treatment with astragaloside IV caused cell cycle arrest at the G0/G1 phase, indicating its anti-tumor effects.
  • Network pharmacology identified multiple pathways, particularly pi3k/akt, targeted by astragaloside IV against glioma.
  • This study highlights the potential of astragaloside IV as a therapeutic agent in glioma treatment.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68f5fcd68d54a28a75cf2109https://doi.org/10.47310/jpms2025140904
View Full Paper
Ask AI
Bookmark
Share